Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
By A. Widge, N. Rouphael, L. Jackson, E. Anderson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers and 21 more. New England Journal of Medicine, 2020
705 citations recorded by the source corpus.
Immunogenicity and Moderna’s SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers...
Subfields: Animal Science and Zoology, Immunology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/17fcd35f1e9450a12f14db8c864d03f84be9bac6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- A human coronavirus evolves antigenically to escape antibody immunity (2020, background): “Our reason for focusing on these sera is that their anti-229E neutralizing titers are comparable to anti-SARS-CoV-2 sera neutralizing titers several months after recovery from COVID-19 [13,16] or receipt of the Moderna mRNA-1273 vaccine [49].”